FMTVDM Provides a Paradigm Shifting Approach for Medical Science. Moving from "I Think I See Something" to "I Know What I See & I Know Exactly How Much and How Active What I See Is!"
To Quote a 2024 Presidential Candidate,
"What can be, unburdened by what has been."
Unlike the platitude used in the presidential campaign, science, including medical science, moves forward - sometimes in small steps, sometimes in strides and sometimes in paradigm shifts. Approaches not previously appreciated or understood can be the most challenging for others to accept. Particularly if it means others will lose out on money or attention. But ultimately they will be accepted and embraced.
Focusing on whether others embrace our work would only mean our attention would be shifted from future advancements, to the past and the past is only associated with "what has been" and not "what can be."
​
Scientists like myself are less focused with how rapidly others will embrace our work and more focused on what the next task or challenge lies before us. Sometimes it feels like wandering in the desert.
What are I missing?
What should I be considering and/or doing next?
What should I be thinking about or working on to continue forward?
​
Answers to these questions have lead me down the pathway of integrating the ITIRD theory and FMTVDM. Investigations into the understanding of the ramifications of understanding and measuring regional blood flow and metabolic differences in tissue within the living organism - including both people, animals and plants (chloroplasts) - has resulted in understanding the true cause of angina, finding heart disease and other health problems earlier, allowing less toxic treatments and better outcomes with people living longer, healthier lives, without the chronic ITIR diseases (ITIRDs).
​
By coupling the ITIRD theory with FMTVDM, along with the proprietary coronary blood flow equation that I developed in 1990 using 40% of the world quantitative coronary arteriography database, FMTVDM provides multiple benefits including but not limited to the following:
​
1) The first and so far only quantitative method for measuring heart disease using nuclear imaging,
​
2) Could quantitatively calculate using the proprietary flow reserve equation differences in regional coronary blood flow, thereby finding the cause of an individuals coronary angina,
​
3) Derive anatomic disease (percent diameter lumen narrowing frequently referred to as percent diameter stenosis; i.e. %DS) from the derived coronary artery flow reserve determined by measuring actual differences in isotope from the different coronary vascular beds,
​
4) Derived differences in heart disease across the full thickness of the heart, including the endocardium where problems first develop resulting in heart damage before it shows up on the electrocardiogram; salvaging heart pump function to minimize damage that would result in heart failure, and
​
5) Allow determination of whether heart disease treatment was working or failing in the person being studied.
​
The following are just some of the published research papers that have resulted from questioning what has been and seeking what can be. They answer the fundamental questions of how can we diagnose health problems sooner, safer, with less radiation, less toxicity, and what can we do to make people healthier and what do we need to stop doing that has produced our chronic ITIRD epidemic?
​
By 2019 I was ready to begin licensing FMTVDM at selected University Medical Centers and then 2019 happened. Like you, my attention was turned elsewhere and as you will see, I used FMTVDM to answer many questions about treatment for COVID - including publishing that information in peer reviewed medical journals AND presenting at several medical conferences.
​
Unfortunately, the COVID pandemic, while useful for showing the benefit of understanding the ITIRD theory and application of FMTVDM, resulted in the delay of launching FMTVDM. But like other delays, it was only temporary.
​
For the remainder of this page, I will present some of the work using FMTVDM for the detection and treatment of heart disease.
​​
​​